Eli Lilly and Company (LLY)
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
2 Stocks That Could Split Very Soon
Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a split.
Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday at the Leerink Partners Global Healthcare Conference.
Big Money Returning for Eli Lilly
Obesity drugs, durable revenue bringing Big Money investors to Eli Lilly and Company (LLY).
US judge denies injunction to stop bar on copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
Whatever you think of Donald Trump's tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.
Eli Lilly and Company (LLY) TD Cowen 45th Annual Health Care Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) TD Cowen 45th Annual Health Care Conference March 4, 2025 1:50 PM ET Company Participants Jake Van Naarden - President of Lilly Oncology Conference Call Participants Stephen Scala - TD Cowen Stephen Scala Good afternoon, and welcome once again to TD Cowan's 45 Annual Health Care Conference. We're delighted to have with us, again this year, Eli Lilly.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
Where Will Eli Lilly Be in 5 Years?
It's hard to argue with the kinds of results Eli Lilly (LLY 1.71%) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving the broader market in the dust.
Eli Lilly takes aim at weight-loss drug copies with new ad campaign
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.
Eli Lilly investing $27B more in US manufacturing
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.
